Skip to main content

Articles

New Perspectives in the Treatment of Opioid-Induced Respiratory Depression

FDA Approves New Injectable Drug to Treat Schizophrenia

Optimizing Rheumatoid Arthritis Therapy: Using Objective Measures of Disease Activity to Guide Treatment

Stakeholder Perspective

Closing Gaps in Health Plan Performance with Stakeholder Collaboration

Evaluating the Expected Costs and Budget Impact of Interventional Therapies for the Treatment of Chronic Venous Disease

Stakeholder Perspective

A Teachable Moment in Health Benefits Design

Transforming the Drug Cost Paradigm from Payment for Medications to Payment for Value

Healthcare Utilization and Costs of Knee or Hip Replacements versus Pain-Relief Injections

Stakeholder Perspective

Knee and Hip Pain: Rewarding Optimal Long-Term Management

Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder

Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer

The Continuing Clinical and Economic Burden of Cardiometabolic Health

Page 126 of 244
Results 1251 - 1260 of 2439